Reveal Deeper MRD
with ClonoSIGHT™

Detection of minimal residual disease (MRD) is the best way to predict which patients with lymphoid cancers will relapse.

Sequenta’s ClonoSIGHT test enables physicians to utilize sequencing-based MRD detection as a clinical decision-making tool.

A two-step process

Cancer monitoring with the ClonoSIGHT test is a
two-step process that identifies and then tracks
cancer clones over time.

Infographic

The ClonoSIGHT Workflow

  • LymphoSIGHT Slider 1
  • LymphoSIGHT Slider 2
  • LymphoSIGHT Slider 3
  • LymphoSIGHT Slider 4
  • LymphoSIGHT Slider 5
  • LymphoSIGHT Slider 6
  • LymphoSIGHT Slider 7
  • LymphoSIGHT Slider 8
  • LymphoSIGHT Slider 9
01